Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06812390 · ClinicalTrials.gov registry record · Phase 2
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
A Phase 2 study of Cirrhosis and Ascites Hepatic, sponsored by Anahita Rabiee MD MHS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06812390: Recruiting Phase 2 study of Cirrhosis and Ascites Hepatic, sponsored by Anahita Rabiee MD MHS.
NCT06812390 is a Phase 2 study of Cirrhosis and Ascites Hepatic that is actively recruiting participants, run by Anahita Rabiee MD MHS. The registered enrollment target is 20 participants, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06812390, a Phase 2 study of Cirrhosis and Ascites Hepatic, is actively recruiting participants, sponsored by Anahita Rabiee MD MHS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.
Primary Outcome
Change in fractional excretion of sodium (FENa) with administration of albumin vs placebo
Conditions Studied
Interventions
- DRUG Normal Saline (0.9% NaCl)
- DRUG Albumin infusion (25% albumin)
Study Locations (1)
Connecticut
- West Haven VA Medical Center - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
What NCT06812390 shows while recruiting
NCT06812390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline (0.9% NaCl) is the first listed.
NCT06812390 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06812390 about?
NCT06812390 is a clinical study titled "Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites". A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.
What is the current status of trial NCT06812390?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-02-28. Estimated completion is 2027-03.
What conditions does trial NCT06812390 study?
This clinical trial studies the following conditions: Cirrhosis, Ascites Hepatic.
What interventions are being tested in trial NCT06812390?
The interventions under investigation include: Normal Saline (0.9% NaCl) (DRUG), Albumin infusion (25% albumin) (DRUG).
Who is sponsoring clinical trial NCT06812390?
This trial is sponsored by Anahita Rabiee MD MHS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06812390 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06812390's enrollment target sits among peer trials
20 44th of 53 higher than 8 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
RECRUITING · Phase 2
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI